Fact check: How deadly was 2024 for journalists?
An estimated 104 journalists lost their lives in 2024, with Palestine the most dangerous territory. Read More
Romanian centre-right party’s TikTok campaign used for far-right win — report
A communications agency picked influencers to make TikTok videos about the qualities of a future Romanian president for the centre-right PNL party, endorsing little-known ultranationalist Georgescu instead. Read More
North Korea to send more troops and weapons to help Russia in its war against Ukraine
North Korea to send more troops and weapons to help Russia in its war against Ukraine Read more at Read More
Little reason for cheer as drought forces Spain to ration Cava wine production
Sales of cava, the Spanish sparkling wine, are down globally thanks to bad weather affecting vineyards but industry leaders have a plan to reverse their flagging fortunes. Read More
How the 2004 Indian Ocean tsunami became a ‘wake up call’ for early warning systems
The Indian Ocean tsunami which struck on 26 December 2004 killed more than 220,000 people. Read More
Japanese car makers Nissan and Honda announce plans to merge
The move will create the world’s third-largest car maker by sales, as the industry undergoes dramatic changes in its transition away from fossil fuels. Read More
New York City police arrest man after woman set on fire and killed on subway train
New York City police arrest man after woman set on fire and killed on subway train Read more at Read More
From street protests to an Airbnb ban, all the ways Barcelona said no to tourists in 2024
Spain’s most visited city is seeking quality over quantity in 2025. Read More
Festive rally for European markets? 10 stocks to watch for Christmas gains
December often sees robust equity market gains, particularly in the second half. Seasonal optimism, portfolio rebalancing, and reduced volatility make it one of the strongest periods for European stocks, especially…
Novo Nordisk shares plunge on the back of disappointing trial results
Novo Nordisk shares have plunged 20% amid the disappointing trial result of its latest weight-loss drug CagriSema. The fall wiped out €90bn in market valuation on Friday. Read More